Akitoshi Takuma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Akitoshi Takuma has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Kenji Momo
Division of Clinical Research, Department of Hospital Pharmaceutics, School of Pharmacy Showa Medical University Tokyo Japan
2 shared publications - Atsushi Tomizawa
Department of Pharmacy, Kitasato University Hospital, Sagamihara, Japan
1 shared publication Ayako Suzuki
Department of Pharmacy, Showa University Fujigaoka Hospital, Yokohama, Japan
1 shared publicationErika Inoue
Department of Pharmacy, Showa University Northern Yokohama Hospital, Chigasaki Chuo 35-1, Tsuzuki-ku, Yokohama City Kanagawa, 224-8503, Japan
1 shared publication- Fumihiro Yamaguchi
Department of Respiratory Medicine, Showa Medical University Fujigaoka Hospital , Yokohama
1 shared publication Fumio Nagumo
Department of Pharmacy, Yokohama General Hospital, Yokohama, Japan
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 14
Linezolid as a potential alternative to glycopeptide in treating Enterococcus faecium suspected cyst infection in a hemodialysis patient with autosomal-dominant polycystic kidney disease: A case report
Autosomal-dominant polycystic kidney disease is a clinically significant disorder associated with progressive renal impairment. In these patients, cyst infection is an important but variably occurring complication, and optimal antibiotic selection remains challenging owing to the limited available evidence and restricted antibiotic penetration into cysts. An 81-year-old Japanese man with autosomal-dominant polycystic kidney disease undergoing maintenance hemodialysis presented with fever and a suspected cyst infection. Blood cultures showed the fluoroquinolone-resistant Enterococcus faecium . Vancomycin was contraindicated due to allergy, and teicoplanin was ineffective. Oral linezolid was initiated, resulting in clinical improvement. However, treatment was discontinued after 15 days of therapy (on hospital day 27) because of grade 1 thrombocytopenia. This case contributes to the limited clinical evidence in this field and highlights the potential role of linezolid in the management of Enterococcus faecium suspected cyst infections in autosomal-dominant polycystic kidney disease when glycopeptides are ineffective or contraindicated.
- 1 January 2026
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 14
Open AccessLinezolid as a potential alternative to glycopeptide in treating Enterococcus faecium suspected cyst infection in a hemodialysis patient with autosomal-dominant polycystic kidney disease: A case report
Autosomal-dominant polycystic kidney disease is a clinically significant disorder associated with progressive renal impairment. In these patients, cyst infection is an important but variably occurring complication, and optimal antibiotic selection remains challenging owing to the limited available evidence and restricted antibiotic penetration into cysts. An 81-year-old Japanese man with autosomal-dominant polycystic kidney disease undergoing maintenance hemodialysis presented with fever and a suspected cyst infection. Blood cultures showed the fluoroquinolone-resistant Enterococcus faecium . Vancomycin was contraindicated due to allergy, and teicoplanin was ineffective. Oral linezolid was initiated, resulting in clinical improvement. However, treatment was discontinued after 15 days of therapy (on hospital day 27) because of grade 1 thrombocytopenia. This case contributes to the limited clinical evidence in this field and highlights the potential role of linezolid in the management of Enterococcus faecium suspected cyst infections in autosomal-dominant polycystic kidney disease when glycopeptides are ineffective or contraindicated.
- 3 November 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 30 (4) , 329-336
Flowchart for predicting achieving the target area under the concentration-time curve of vancomycin in critically ill Japanese patients: A multicenter retrospective study
- 3 November 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 30 (4) , 329-336
Flowchart for predicting achieving the target area under the concentration-time curve of vancomycin in critically ill Japanese patients: A multicenter retrospective study
- 22 October 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (2) , 208-211
Failure of liposomal amphotericin B therapy in patients with severe pancreatitis complicated by Candida lusitaniae infection
- 22 October 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (2) , 208-211
Failure of liposomal amphotericin B therapy in patients with severe pancreatitis complicated by Candida lusitaniae infection